Lixar (lixivaptan) / Centessa 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  CARACTERIZACI (TUE-107; Main Foyer) -  Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1149;    
    Los pacientes que presentan una progresi
  • ||||||||||  tolvaptan / Generic mfg.
    Journal:  Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan. (Pubmed Central) -  Dec 13, 2022   
    Herein, we addressed this question through the exposure of tolvaptan-responsive T-cell clones to similar pharmaceutical agents. Whilst lixivaptan and conivaptan did not activate tolvaptan-responsive T-cells, mozavaptan evoked proliferative responses comparable with tolvaptan itself, indicating that there may be collateral immunological intolerance to this compound as a product of sensitization to tolvaptan.
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Enrollment change, Trial termination:  Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) -  Oct 31, 2022   
    P3,  N=7, Terminated, 
    Whilst lixivaptan and conivaptan did not activate tolvaptan-responsive T-cells, mozavaptan evoked proliferative responses comparable with tolvaptan itself, indicating that there may be collateral immunological intolerance to this compound as a product of sensitization to tolvaptan. N=50 --> 7 | Active, not recruiting --> Terminated; The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with ADPKD
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Enrollment change, Trial termination:  Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303 (clinicaltrials.gov) -  Aug 31, 2022   
    P3,  N=1, Terminated, 
    N=50 --> 7 | Active, not recruiting --> Terminated; The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with ADPKD N=12 --> 1 | Active, not recruiting --> Terminated; The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with ADPKD.
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  ACTION: Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) -  Aug 29, 2022   
    P3,  N=12, Terminated, 
    N=12 --> 1 | Active, not recruiting --> Terminated; The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with ADPKD. N=1350 --> 12 | Trial completion date: Apr 2026 --> Aug 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2025 --> Aug 2022; The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with autosomal dominant polycystic kidney disease (ADPKD).
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Enrollment closed, Trial completion date, Trial primary completion date:  Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) -  Jun 9, 2022   
    P3,  N=50, Active, not recruiting, 
    N=1350 --> 12 | Trial completion date: Apr 2026 --> Aug 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2025 --> Aug 2022; The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with autosomal dominant polycystic kidney disease (ADPKD). Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Oct 2022 | Trial primary completion date: Dec 2023 --> Sep 2022
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Enrollment closed, Trial completion date, Trial primary completion date:  Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303 (clinicaltrials.gov) -  Jun 8, 2022   
    P3,  N=12, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Oct 2022 | Trial primary completion date: Dec 2023 --> Sep 2022 Enrolling by invitation --> Active, not recruiting | Trial completion date: Jul 2026 --> Oct 2022 | Trial primary completion date: Jul 2026 --> Sep 2022
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Phase classification:  Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease (clinicaltrials.gov) -  Oct 14, 2021   
    P=N/A,  N=0, No Longer Available, 
    The potential for synergy between these two compounds suggested in these animal studies, if confirmed in appropriate clinical investigations, would represent a welcome advancement in the treatment of ADPKD. Phase classification: P2 --> P=N/A
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Journal:  Revisit ligand-receptor interaction at the human vasopressin V receptor: A kinetic perspective. (Pubmed Central) -  Mar 25, 2021   
    Our results showed that the antagonist with longer receptor residence time (lixivaptan) displayed sustained target occupancy than the antagonist with shorter receptor residence time (mozavaptan)...Together, our data provide evidence that binding kinetics, next to their affinity, offers additional information for the dynamic process of ligand-receptor interaction. Hopefully, this study may lead to more kinetics-directed medicinal chemistry efforts and aid the design and discovery of different-in-class of vasopressin V receptor ligands for clinical applications.
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Trial completion date, Trial primary completion date:  ACTION: Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) -  Jan 29, 2021   
    P3,  N=1200, Not yet recruiting, 
    Hopefully, this study may lead to more kinetics-directed medicinal chemistry efforts and aid the design and discovery of different-in-class of vasopressin V receptor ligands for clinical applications. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Dec 2024
  • ||||||||||  Lixar (lixivaptan) / Palladio
    Journal:  Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells. (Pubmed Central) -  May 15, 2020   
    Compared to tolvaptan-a selective V2R antagonist indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia-lixivaptan has been predicted to be less likely to cause liver injury...Consistent with this finding, real-time fluorescence kinetic measurements demonstrated that lixivaptan prevented dDAVP-induced increase in osmotic water permeability. These data represent the first detailed demonstration of the central role of AQP2 blockade in the aquaretic effect of lixivaptan and suggest that lixivaptan has the potential to become a safe and effective therapy for the treatment of disorders characterized by high plasma vasopressin concentrations and water retention.
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Trial completion date, Trial initiation date, Trial primary completion date:  ACTION: Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) -  May 7, 2020   
    P3,  N=1200, Not yet recruiting, 
    These data represent the first detailed demonstration of the central role of AQP2 blockade in the aquaretic effect of lixivaptan and suggest that lixivaptan has the potential to become a safe and effective therapy for the treatment of disorders characterized by high plasma vasopressin concentrations and water retention. Trial completion date: Apr 2024 --> Oct 2024 | Initiation date: Oct 2020 --> Apr 2021 | Trial primary completion date: Oct 2023 --> Apr 2024
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Trial completion date, Trial initiation date, Trial primary completion date:  Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) -  May 7, 2020   
    P3,  N=50, Not yet recruiting, 
    Trial completion date: Apr 2024 --> Oct 2024 | Initiation date: Oct 2020 --> Apr 2021 | Trial primary completion date: Oct 2023 --> Apr 2024 Trial completion date: Jul 2022 --> Nov 2022 | Initiation date: Mar 2020 --> Jul 2020 | Trial primary completion date: Jun 2022 --> Oct 2022
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Trial completion date, Trial primary completion date:  Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease (clinicaltrials.gov) -  Jan 30, 2020   
    P2,  N=1, Enrolling by invitation, 
    Initiation date: Mar 2020 --> Oct 2020 | Trial primary completion date: Mar 2023 --> Oct 2023 Trial completion date: Mar 2020 --> Jan 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Samsca (tolvaptan) / Otsuka
    Journal:  Hyponatremia in Heart Failure: Pathogenesis and Management. (Pubmed Central) -  Nov 21, 2019   
    In recent years, a few strategies, such as AVP antagonists (Tolvaptan, Conivaptan, and Lixivaptan), and hypertonic saline in addition to loop diuretics, have been proposed as potentially promising treatment options for this condition. This review aimed to summarize the current literature on pathogenesis and management of hyponatremia in patients with HF.
  • ||||||||||  Lixar (lixivaptan) / Centessa
    Trial completion date, Trial primary completion date:  The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (clinicaltrials.gov) -  Nov 1, 2019   
    P2,  N=32, Recruiting, 
    This review aimed to summarize the current literature on pathogenesis and management of hyponatremia in patients with HF. Trial completion date: Sep 2019 --> Feb 2020 | Trial primary completion date: Aug 2019 --> Jan 2020
  • ||||||||||  Vaptans, New-Generation Diuretics, Exert Their Aquaretic Effect Through Inhibition of Aquaporin 2 Trafficking in Renal Collecting Duct Cells () -  Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5424;    
    Compared to tolvaptan - a selective V2R antagonist indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia -, lixivaptan has been predicted to be less likely to cause liver injury...Conclusion These data represent the first detailed demonstration of the central role of AQP2 blockade in the aquaretic effect of lixivaptan and suggest that lixivaptan has the potential to become a safe and effective therapy for the treatment of disorders characterized by high plasma vasopressin concentrations and water retention. Funding Commercial Support
  • ||||||||||  Jynarque (tolvaptan) / Otsuka, Lixar (lixivaptan) / Palladio
    Dual Targeting of the G Protein-Coupled Receptors CaSR and V2R for Treating Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_2602;    
    Simulations on a multiscale computational model of drug-induced liver injury indicate that the novel V2R antagonist lixivaptan has a safer liver profile...The potential for synergy between these two compounds suggested in these animal studies warrants further investigation in clinical settings. Funding Commercial Support